88,021 Shares in Baxter International Inc. $BAX Purchased by Quantitative Investment Management LLC

Quantitative Investment Management LLC acquired a new stake in Baxter International Inc. (NYSE:BAX) during the 3rd quarter, HoldingsChannel.com reports. The fund acquired 88,021 shares of the medical instruments supplier’s stock, valued at approximately $2,004,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BAX. Cooke & Bieler LP increased its stake in shares of Baxter International by 25.7% in the third quarter. Cooke & Bieler LP now owns 2,200,860 shares of the medical instruments supplier’s stock valued at $50,114,000 after purchasing an additional 450,350 shares during the period. Russell Investments Group Ltd. boosted its position in shares of Baxter International by 32.4% during the third quarter. Russell Investments Group Ltd. now owns 2,515,928 shares of the medical instruments supplier’s stock worth $57,243,000 after buying an additional 615,100 shares during the period. Greenhaven Associates Inc. acquired a new position in shares of Baxter International during the third quarter worth approximately $143,186,000. Cullen Capital Management LLC grew its holdings in Baxter International by 10.4% in the 2nd quarter. Cullen Capital Management LLC now owns 1,651,542 shares of the medical instruments supplier’s stock worth $50,009,000 after buying an additional 155,415 shares in the last quarter. Finally, Stoneridge Investment Partners LLC bought a new position in Baxter International in the 3rd quarter worth approximately $2,128,000. 90.19% of the stock is owned by institutional investors and hedge funds.

Baxter International Stock Performance

Shares of NYSE BAX opened at $17.99 on Friday. The stock has a fifty day moving average price of $20.06 and a two-hundred day moving average price of $20.69. The company has a debt-to-equity ratio of 1.55, a quick ratio of 1.56 and a current ratio of 2.31. The firm has a market cap of $9.25 billion, a P/E ratio of -9.72, a PEG ratio of 1.26 and a beta of 0.58. Baxter International Inc. has a 1 year low of $17.00 and a 1 year high of $35.03.

Baxter International (NYSE:BAX) last posted its quarterly earnings data on Thursday, February 12th. The medical instruments supplier reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.53 by ($0.09). Baxter International had a positive return on equity of 16.95% and a negative net margin of 8.51%.The firm had revenue of $2.97 billion during the quarter, compared to the consensus estimate of $2.82 billion. During the same period in the prior year, the firm posted $0.58 EPS. The firm’s quarterly revenue was up 8.0% on a year-over-year basis. Baxter International has set its FY 2026 guidance at 1.850-2.050 EPS. Research analysts forecast that Baxter International Inc. will post 2.48 EPS for the current fiscal year.

Baxter International Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Friday, February 27th will be given a $0.01 dividend. The ex-dividend date is Friday, February 27th. This represents a $0.04 annualized dividend and a yield of 0.2%. Baxter International’s payout ratio is -2.16%.

Analyst Ratings Changes

Several analysts have weighed in on BAX shares. Evercore cut their target price on Baxter International from $24.00 to $23.00 in a research note on Monday, January 5th. Weiss Ratings reissued a “sell (d)” rating on shares of Baxter International in a research note on Wednesday, January 21st. Barclays lowered their price target on Baxter International from $30.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, February 13th. Jefferies Financial Group cut their price objective on shares of Baxter International from $21.00 to $19.00 and set a “hold” rating on the stock in a research note on Friday, February 13th. Finally, Wall Street Zen downgraded shares of Baxter International from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Two research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Baxter International currently has an average rating of “Hold” and a consensus price target of $19.90.

Baxter International Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.